Long-term Outcome of Adult Patients With Membranous Nephropathy Treated With Rituximab.

ABSTRACT:

Introduction

Rituximab (RTX) therapy has become the standard of care for treatment of membranous nephropathy (MN). However, data on hard outcomes such as end-stage kidney disease (ESKD) and loss of estimated glomerular filtration rate (eGFR), are lacking.

Methods

This was a retrospective study on all patients with MN treated with RTX between January 2000 and December 2022. The primary outcomes were ESKD and eGFR loss > 50%. Clinical outcomes were complete remission (CR), partial remission (PR) (reduction in baseline proteinuria ≥ 50% and proteinuria ≤ 3.5 g/24 h), and immunological remission (IR) (serum antiphospholipase A receptor antibody [PLA2R-Ab] depletion).

Results

A total of 159 patients were included (75.5% male, 87.4% White, median age: 58 years); 52.8% had p

SUBMITTER: Vargas-Brochero MJ 

PROVIDER: S-EPMC12348103 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature